Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.
CDFF332A12101
Phase 1 other active
Quick answer
Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors. for Advanced, relapsed Clear Cell Renal Cell Carcinoma is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advanced, relapsed Clear Cell Renal Cell Carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active